GUMIS
Microbiome, diabetes, metabolic syndrome, obesity, cardiovascular diseases, next generation probiotics
Research Area Nutrition & Metabolism
Glucoregulatory role of gut microbes through GLP-1 signalling- GUMIS. Project funded by EFSD and Boehringer Ingelheim European Research Programme on “Multi-System Challenges in Diabetes, Obesity and Cardiometabolic Disease” 2024. Principal Investigators of CSIC: Yolanda Sanz; Co-IP1: Valentina Tremaroli Co-IP2: Marina Romani-Perez.
GUMIS investigates whether intestinal bacterium Holdemanella biformis G59 exerts a glucoregulatory effect through improvements in GLP-1 signaling from the gut to the brain and thus, amplifies the effectiveness of glucose-lowering drugs (analogs of GLP-1, GLP-1RA).
Objectives
- To determine the causal role of bacterium H. biformis in improving glucose metabolism specifically through GLP-1 signaling via the gut-brain axis.
- To evaluate whether the bacterium could amplify the action of GLP-1RA and, thus, potentiate the efficacy and reduce the therapeutic doses and side effects.
- Validate associations between H. biformis, T2D and glucose-lowering drug use.
Impact
- Improving quality of life of patients and at-risk subjects of type 2 diabetes, metabolic syndrome and cardiovascular diseases.